<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455115</url>
  </required_header>
  <id_info>
    <org_study_id>MAP after Livertransplantation</org_study_id>
    <nct_id>NCT02455115</nct_id>
  </id_info>
  <brief_title>Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure</brief_title>
  <official_title>Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the effects of MAP 60, 75 and 90 mmHg, respectively, on renal blood flow,
      glomerular filtration rate and renal oxygen demand in patients with terminal liver failure
      directly after liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with terminal liver failure are at risk to develop postoperative acute kidney injury
      (AKI) after liver transplantation. This is associated with augmented morbidity (CRRT/HD), and
      mortality. Hypotension perioperatively is a risk factor for the development of postoperative
      AKI.

      In the investigators' study, the researchers aim to investigate the importance of the level
      of mean arterial pressure (MAP) on functional renal parameters directly after liver
      transplantation. 12 patients will be included after given informed and written consent.

      Directly after the operation, the patients stay sedated and ventilated, have reached
      normovolaemia and are in need of vasopressor for adequate blood pressure. MAP is varied using
      the vasopressor norepinephrine.

      Central hemodynamics will be measured using arterial catheter, PiCCO and a central vein
      catheter.

      Renal data measures (RBF (renal blood flow), RPF (renal plasma flow), FF (filtration
      fraction), GFR (glomerular filtration rate), RVR (renal vascular resistance), Arterial-renal
      vein oxygen content difference, RVO2 (renal oxygen consumption), and RO2extr (Renal oxygen
      extraction)), are conducted via a renal vein thermodilution catheter: A 8-Fr catheter is
      introduced into the left or right renal vein, via the right femoral vein under fluoroscopic
      guidance, position being confirmed by venography using ultra-low doses of iohexol.

      After the collection of blood and urine blanks, an intravenous priming dose of chromium
      ethylenediaminetetraacetic acid (51Cr-EDTA) is given, followed by an infusion at a constant
      rate, individualized to BSA and preoperative serum creatinine. Serum 51Cr-EDTA activity from
      arterial and renal vein blood is measured using a well counter. FF is measured as extraction
      of Cr-EDTA.

      After one hour and two control measurements and urine/blood sampling on baseline MAP 75 mmHg,
      the investigators will randomise to continue to MAP 90 mmHg or 60 mmHg reached by altering
      the infusion rate of norepinephrine. Measurements, blood sampling and urine collection
      according to the above description, are performed after 30 min at each level, finishing at 75
      mmHg with two control measurements with 30 mins in between.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glomerular filtration rate (ml/min)</measure>
    <time_frame>60 min at baseline (75 mmHg), 30 min at randomized level 1(either 60 or 90 mmHg), 30 min at randomized level 2 (either 60 or 90 mmHg), 60 min after returning to baseline 75 mmHg again</time_frame>
    <description>Change from baseline 75 mmHg to 60 and 90 mmHg, respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Renal blood flow (ml/min)</measure>
    <time_frame>60 min at baseline (75 mmHg), 30 min at randomized level 1(either 60 or 90 mmHg), 30 min at randomized level 2 (either 60 or 90 mmHg), 60 min after returning to baseline 75 mmHg again</time_frame>
    <description>Measured via retrograde thermodilution catheter placed in renal vein. Change from baseline 75 mmHg to 60 and 90 mmHg, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal oxygen consumption (ml/min)</measure>
    <time_frame>60 min at baseline (75 mmHg), 30 min at randomized level 1(either 60 or 90 mmHg), 30 min at randomized level 2 (either 60 or 90 mmHg), 60 min after returning to baseline 75 mmHg again</time_frame>
    <description>Blood samples and measurements of blood flow via retrograde thermodilution catheter placed in renal vein.
RBF Ã— (CaO2-CrvO2) Change from baseline 75 mmHg to 60 and 90 mmHg, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Filtration fraction (%)</measure>
    <time_frame>60 min at baseline (75 mmHg), 30 min at randomized level 1(either 60 or 90 mmHg), 30 min at randomized level 2 (either 60 or 90 mmHg), 60 min after returning to baseline 75 mmHg again</time_frame>
    <description>Extraction of Cr-EDTA, blood samples from renal vein catheter. Change from baseline 75 mmHg to 60 and 90 mmHg, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal oxygen supply/demand relationship</measure>
    <time_frame>60 min at baseline (75 mmHg), 30 min at randomized level 1(either 60 or 90 mmHg), 30 min at randomized level 2 (either 60 or 90 mmHg), 60 min after returning to baseline 75 mmHg again</time_frame>
    <description>Renal oxygen consumption compared to renal oxygen delivery (CaO2-CrvO2/CaO2). Change from baseline 75 mmHg to 60 and 90 mmHg, respectively.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>60 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alternating mean arterial pressure</intervention_name>
    <description>In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.</description>
    <arm_group_label>60 mmHg</arm_group_label>
    <arm_group_label>75 mmHg</arm_group_label>
    <arm_group_label>90 mmHg</arm_group_label>
    <other_name>Norepinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.</description>
    <arm_group_label>60 mmHg</arm_group_label>
    <arm_group_label>75 mmHg</arm_group_label>
    <arm_group_label>90 mmHg</arm_group_label>
    <other_name>Blood pressure control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chromium ethylenediaminetetraacetic acid</intervention_name>
    <description>Extraction of 51Cr-EDTA measured for FF and GFR</description>
    <arm_group_label>60 mmHg</arm_group_label>
    <arm_group_label>75 mmHg</arm_group_label>
    <arm_group_label>90 mmHg</arm_group_label>
    <other_name>Infusion of 51Cr-EDTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uncomplicated liver transplantation

          -  Age over 18 years

          -  Given informed consent preoperatively

        Exclusion Criteria:

          -  Veno-venous bypass intraoperatively

          -  Uncontrolled postoperative bleeding

          -  Circulatory stability without need for vasopressor treatment

          -  Pronounced circulatory or respiratory instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Skytte Larsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, dpt of anesthesiology and intensive care</name>
      <address>
        <city>GÃ¶teborg</city>
        <state>VGR</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Jenny Skytte Larsson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute kidney injury</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Postoperative care</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Renal blood flow</keyword>
  <keyword>Vasopressor</keyword>
  <keyword>Norepinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

